Study: "Profound" diagnoses of autism are far outnumbered by milder cases.

Published Date: 26 Apr 2023

Health officials have wondered how many U.S. children are being diagnosed with autism as it becomes more common. S. How many children experience more severe symptoms like a very low IQ and verbal immaturity, and how many kids have relatively mild symptoms?

Read Full News

Latest News

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Todays Updates

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Paul Nghiem, MD, PhD

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Todays Updates

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Paul Nghiem, MD, PhD

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Latest News

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

News All Time

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Late-Breaking CHOICE 2 Data Indicate Alteplase Displayed Improved Stroke Recovery Louie Pasculli

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

Subgroup Signals Emerge for rFVIIa in Acute Intracerebral Hemorrhage in Phase 3 FASTEST Trial Marco Meglio

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis Marco Meglio

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis Noah Stansfield

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

Real-World Data Analysis Highlight Clinical Profiles and Inebilizumab Use Patterns in NMOSD Isabella Ciccone, MPH

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

CREST-2 Substudy Shows No Cognitive Benefit of Carotid Revascularization in Asymptomatic Carotid Stenosis Isabella Ciccone, MPH

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

Biomarker Data Across Studies Support Disease-Targeted Effects of Valiltramiprosate Marco Meglio

Newly reported data showed that oral valiltramiprosate lowers p-tau217 and links to cognitive and brain-volume benefits in early Alzheimer disease.

NeuroVoices: Benjamin Tolchin, MD, FAAN, on First-Ever AAN Guidelines for Functional Seizures Marco Meglio

The director of the Center for Clinical Ethics at Yale New Haven Health discussed the rationale behind the newly published AAN guidelines on functional seizures, outlining diagnostic priorities, evidence-based treatment recommendations, and key gaps.

National Women Physicians Day: Learning, Leading, and Lifting Others in Neurology Marco Meglio, Merit Cudkowicz, MD, MSc

ALS expert Merit Cudkowicz, MD, MSc, provided thoughts for National Women Physicians Day, reflecting on resilience in ALS research, the power of mentorship, and how leadership and advocacy can shape a meaningful career in neurology.

National Women Physicians Day: Perspectives From Riley Bove, MD Louie Pasculli, Riley Bove, MD

Riley Bove, MD, MS, associate professor of neurology at the University of California San Francisco, shares her personal view on National Women’s Physician’s and why it’s important for clinicians and patients in the field.

Women Physicians Day 2026: Prioritizing Whole-Person Care for Women With Movement Disorders Isabella Ciccone, MPH, Jill Farmer, DO, MPH, FCPP, DipABLM, Kelly Papesh, DNP, APRN, FNP-C, CMRD, Madhureeta Achari, MD, Joanna Dearlove, MD

As part of National Women Physicians Day, a group of women clinicians discussed various topics in the care for women with movement disorders.

National Women Physicians Day: Insights From Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, Louie Pasculli

Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, director of the JS Sonshine Center, shares her personal view on National Women Physician’s and why it’s important for clinicians and patients in the field.

National Women Physicians Day: Women Driving Change in Neurology Louie Pasculli

In honor of National Women Physician’s Day, the NeurologyLive® team highlighted recent studies on women transforming neurologic care and advancing women’s health.

VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia Marco Meglio

Neurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.

Recommended News For You

Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals

Radiation from CT scans could account for 5% of all cancer cases a year, study suggests

In a study, immune detection of oral cancers is linked to obesity.

Study finds higher breast cancer rates in areas with more air pollution

Treating advanced prostate cancer

In cancer survivors, loneliness is associated with a higher risk of death.

Scientists call into question safety of potential new anticancer treatment

Recommended Articles For You

Treating Methemoglobinemia: What You Need to Know Now! 

Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer 

Demystifying Lymphocytes: Everything You Need to Know  

What You Need to Know About Correcting Calcium Levels in Patients with Low Albumin  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

2.

Implant-based reconstruction linked to increased risk of breast lymphomas

3.

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

4.

Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting

5.

November 2023, Medical Bulletin 04/.

1.

The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide

2.

Unravelling the Mysteries of Monoclonal Gammopathy

3.

Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction

4.

Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models

5.

Octreotide's Efficacy in Reducing Transfusion Requirements in Angiodysplasia Bleeding

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

3.

A New Era in Managing Cancer-Associated Thrombosis

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

5.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot